Can we prevent Acute Kidney Injury?

Sulfateq BV is an innovative biotechnology research company that is developing breakthrough compounds for the prevention of Acute Kidney Injury (AKI). Our compounds emerged from research on hibernation and provide a new mechanism of action for cell protection, organ protection and prophylactic use and they have a huge potential to support drug development for AKI prevention.

Find Out More

Contact

Invest

News

BIO-Europe 2018 – November 5-7

News

BIO-Europe is coming up in less than 2 weeks. Will you be there? If so, make sure that you schedule a meeting with our director Kees van der Graaf. We would be delighted to meet to explore ways that our SUL-compounds could help preventing acute kidney injury. Please...

Hibernation research leads to new medicines

News

Hibernation research leads to new medicines preventing Alzheimer, Diabetes Type 2 and acute kidney injury ‘Kidney tubule cells from hibernators have an increased resistance to oxidative stress compared to non-hibernators. Based on our research into hibernation, we...

Industrial Grant for UMCG and Sulfateq

News

Cooperation Sulfateq and UMCG recognizes with an Industrial Doctorates grant Last August 2018, the Netherlands Organization for Scientific Research (NWO) awarded an Industrial Doctorate grant to a collaborative project between Sulfateq B.V. and the group of Prof. dr....

View All News

Preventing AKI by Hibernation

Sulfateq BV has conducted successful animal studies using its SUL-compounds to inhibit the occurrence of kidney injury following damage. SUL-138 is focused around AKI during invasive (heart) surgery, as successful prophylactic treatment will increase post-operative survival rate and decrease the hospitalization costs. We therefore see huge potential to address this major organ related medical need with SUL-compounds based drug development. At this moment Sulfateq is engaged in final pre-clinical development of SUL-138, i.e. safety pharmacology, while drafting proposals for Phase I and Phase II clinical studies.

U

Why hibernation?

We are inspired by the principles of hibernation. During hibernation mamals protect their body against threatening conditions. Our research has proved that hibernation can also be used for protecting cells, organs an organisms. That is why we use its natural protection process against cooling and rewarming to develop therapeutic applications.

Application

A direct application of our compounds is protecting organs and body during major surgeries. Acute Kidney Injury (AKI) can occur during various medical operations, one of which is cardiac surgery. We regard this medical need as the most direct opportunity for the application of SUL-compounds as a medical prophylactic treatment.

Investment opportunity

There is no therapy available for kidney protection, or organ protection in general, during major surgery. With our SUL-138 compound we can change this. To advance the clinical development we are seeking investors who we can offer a high-profit business model with high-potential opportunities focussing on pharmaceutical blockbuster markets.

Why does Acute Kidney Injury matter?

Acute Kidney Injury is the sudden loss of kidney function and it affects more than 1.2 million people each year in the United States alone. It occurs in different situations and is particularly frequent in patients hospitalized for major surgery. Currently there is no therapy or drugs available for the protection against AKI during major surgery.



Affects 1/3 of cardiac patients



Increases hospital costs



Lengthens hospital stay



Increases readmission rate



Rises mortality for 10x